

BIOMARIN PHARMACEUTICAL INC  
 Form 4  
 July 18, 2008

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL  
 OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**KAKKIS EMIL D**

2. Issuer Name and Ticker or Trading Symbol  
**BIOMARIN PHARMACEUTICAL INC [BMRN]**

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 Chief Medical Officer

(Last) (First) (Middle)  
**C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE**  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
**07/07/2008**

**NOVATO, CA 94949**  
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Code | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|---------|---|---|--|-----------------------------------|
|                                 |                                      |  |         | (A) or (D)  | Price   |  |                                   |
| Common Stock                    | 07/07/2008 <sup>(1)</sup>            | 07/07/2008   | S       | 900   | D \$ 27.9   | 162,404  | D                                 |
| Common Stock                    | 07/07/2008 <sup>(1)</sup>            | 07/07/2008   | S       | 800   | D \$ 27.91  | 161,604  | D                                 |
| Common Stock                    | 07/07/2008 <sup>(1)</sup>            | 07/07/2008   | S       | 200   | D \$ 27.93  | 161,404  | D                                 |
| Common Stock                    | 07/07/2008 <sup>(1)</sup>            | 07/07/2008   | S       | 400   | D \$ 27.94  | 161,004  | D                                 |
|                                 | 07/07/2008 <sup>(1)</sup>            | 07/07/2008   | S       | 100   | D   | 160,904  | D                                 |

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

|              |                           |            |   |       |   |          |         |                       |
|--------------|---------------------------|------------|---|-------|---|----------|---------|-----------------------|
| Common Stock |                           |            |   |       |   | \$ 27.95 |         |                       |
| Common Stock | 07/07/2008 <sup>(1)</sup> | 07/07/2008 | S | 600   | D | \$ 27.96 | 160,304 | D                     |
| Common Stock | 07/07/2008 <sup>(1)</sup> | 07/07/2008 | S | 800   | D | \$ 27.98 | 159,504 | D                     |
| Common Stock | 07/07/2008 <sup>(1)</sup> | 07/07/2008 | S | 3,000 | D | \$ 28    | 156,504 | D                     |
| Common Stock | 07/07/2008 <sup>(1)</sup> | 07/07/2008 | S | 1,700 | D | \$ 28.01 | 154,804 | D                     |
| Common Stock | 07/07/2008 <sup>(1)</sup> | 07/07/2008 | S | 600   | D | \$ 28.02 | 154,204 | D                     |
| Common Stock | 07/07/2008 <sup>(1)</sup> | 07/07/2008 | S | 1,000 | D | \$ 28.03 | 153,204 | D                     |
| Common Stock | 07/07/2008 <sup>(1)</sup> | 07/07/2008 | S | 3,800 | D | \$ 28.06 | 149,404 | D                     |
| Common Stock | 07/07/2008 <sup>(1)</sup> | 07/07/2008 | S | 100   | D | \$ 28.17 | 149,304 | D                     |
| Common Stock | 07/07/2008 <sup>(1)</sup> | 07/07/2008 | S | 100   | D | \$ 28.2  | 149,204 | D                     |
| Common Stock | 07/07/2008 <sup>(1)</sup> | 07/07/2008 | S | 100   | D | \$ 28.21 | 149,104 | D                     |
| Common Stock | 07/07/2008 <sup>(1)</sup> | 07/07/2008 | S | 300   | D | \$ 28.22 | 148,804 | D                     |
| Common Stock | 07/07/2008 <sup>(1)</sup> | 07/07/2008 | S | 3,500 | D | \$ 28.26 | 145,304 | D                     |
| Common Stock |                           |            |   |       |   |          | 4,654   | I                     |
|              |                           |            |   |       |   |          |         |                       |
|              |                           |            |   |       |   |          |         | Shares held by spouse |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned (Instr. 5) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|--|
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|--|

(A) or  
 Disposed  
 of (D)  
 (Instr. 3,  
 4, and 5)

Repor  
 Trans  
 (Instr

| Code | V | (A) | (D) | Date<br>Exercisable | Expiration<br>Date | Title | Amount<br>or<br>Number<br>of<br>Shares |
|------|---|-----|-----|---------------------|--------------------|-------|--|
|------|---|-----|-----|---------------------|--------------------|-------|--|

## Reporting Owners

### Reporting Owner Name / Address

### Relationships

| Director | 10% Owner | Officer | Other |
|----------|-----------|---------|-------|
|----------|-----------|---------|-------|

KAKKIS EMIL D  
 C/O BIOMARIN PHARMACEUTICAL INC.  
 105 DIGITAL DRIVE  
 NOVATO, CA 94949

Chief Medical Officer

## Signatures

G. Eric Davis,  
 Attorney-in-Fact

07/18/2008

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to a Rule10b5-1 Trading Plan executed March 1, 2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.